Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + amifostine + filgrastim
- Development stage
- Unknown
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination chemotherapy regimen was investigated in a Phase I clinical trial conducted at Roswell Park Cancer Institute for the treatment of advanced, recurrent, or metastatic cancers, including solid tumors, leukemia, and lymphoma. The regimen consists of four components: **paclitaxel**, a microtubule-stabilizing small molecule that inhibits cell division; **carboplatin**, a platinum-based antineoplastic agent that induces DNA cross-linking and apoptosis; **amifostine**, a cytoprotective prodrug administered to reduce the cumulative renal and hematologic toxicities associated with chemotherapy; and **filgrastim** (G-CSF), a recombinant granulocyte colony-stimulating factor used to stimulate white blood cell production and support immune recovery. The trial was designed as a dose-escalation study to evaluate the safety and effectiveness of this modulated combination in patients with advanced malignancies.
- Brand names
- TaxolParaplatinEthyolNeupogen
- Other names
- Paclitaxel and Carboplatin with Amifostine and G-CSF
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNACSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on paclitaxel + carboplatin + amifostine + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + amifostine + filgrastim.